Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721262 · ClinicalTrials.gov registry record
Ferumoxytol Enhanced Hyperfine Low Field Strength MRI
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 2
- Enrollment target
NCT04721262: Completed study, sponsored by University of Pennsylvania.
NCT04721262 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04721262 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to evaluate the feasibility of using Ferumoxytol as a contrast agent on a low field strength, portable magnetic resonance imaging (MRI) system. Participants receiving Ferumoxytol as part of routine clinical care for iron deficiency anemia will be recruited and scanned on the Hyperfine MRI system before and after their clinically scheduled intravenous infusion. Resultant images will be compared to assess signal intensity changes generated by the presence of Feromoxytol.
Primary Outcome
Changes in MRI signal intensity (contrast enhancement) produced by the presence of the Ferumoxytol contrast agent will be quantified by co-registering brain MRI studies obtained before and after administration of Ferumoxytol and determining the ratio of signal intensity values between the two sets of images (post-Ferumoxytol/pre-Ferumoxytol) in regions of interest placed separately over brain parenchyma or vascular structures. Based on the magnetic properties of Ferumoxytol, this contrast ratio
Interventions
- DEVICE Hyperfine Portable MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2022-08-29 |
What the finished NCT04721262 record still lists
NCT04721262 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Hyperfine Portable MRI is the first listed.
NCT04721262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04721262 about?
NCT04721262 is a clinical study titled "Ferumoxytol Enhanced Hyperfine Low Field Strength MRI". The purpose of this pilot study is to evaluate the feasibility of using Ferumoxytol as a contrast agent on a low field strength, portable magnetic resonance imaging (MRI) system. Participants receiving Ferumoxytol as part of routine clinical care for iron deficiency anemia will be recruited and scan...
What is the current status of trial NCT04721262?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2020-11-09. Estimated completion is 2022-08-29.
What interventions are being tested in trial NCT04721262?
The interventions under investigation include: Hyperfine Portable MRI (DEVICE).
Who is sponsoring clinical trial NCT04721262?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI